-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Reiterates Outperform on Sutro Biopharma, Maintains $60 Price Target

Benzinga·10/15/2026 13:12:46
语音播报
Wedbush analyst David Nierengarten reiterates Sutro Biopharma (NASDAQ:STRO) with a Outperform and maintains $60 price target.